Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antioxidants and cataracts

This article was originally published in The Tan Sheet

Executive Summary

Roche European American Cataract Trial (REACT) finds three-year daily use of antioxidant cocktail produces "small deceleration in progression of [age-related cataract]," Leo Chylack, MD, Brigham & Women's Hospital, Boston, et al., report in November Ophthalmic Epidemiology. Partly funded by Hoffmann-La Roche and Roche Vitamins, trial included 297 American and British early ARC patients randomly dosed with placebo or combinations of 18 mg beta carotene, 750 mg vitamin C, 600 mg vitamin E. Cataract severity was documented using serial digital retroillumination imagery, progression was measured as "increase % pixels opaque." Findings follow recent research showing antioxidants and zinc reduce risk of developing advanced age-related macular degeneration (1"The Tan Sheet" Oct. 15, p. 3)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS093299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel